HomeDry Eyes and Menopause

WOMEN’S EYE WELLNESS

Dry Eyes and Menopause

Discover why dry eyes and menopause often occur together. Explore effective solutions and improve eye comfort with TheraLife® today.

Hormonal changescan affect the ocular surface and natural tear stability.

Why Menopause Cause Dry Eyes?

Menopause can cause dry eyes because there are hormone receptors located on several key structures of the eye (the cornea, conjunctiva and meibomian glands) that are responsible for the integrity of the ocular surface. In pre-menopausal and post-menopausal women, hormone imbalance can result in unstable make-up of the tear film, causing chronic dry eyes–an inflammatory condition. TheraLife® can help!

CorneaOcular surface integrity

ConjunctivaMoisture and protection

Meibomian glandsTear-film lipid support

TARGETED EYE SUPPORT

TheraLife® Eye

TheraLife® Eye Enhanced has been clinically shown to stimulate tear secretion glands intracellularly (from within their cells) to allow you to produce balanced, natural tears from your own eyes.

TheraLife® Eye Enhanced is designed to restore both tear volume and tear thickness to normal levels and provide long-lasting relief for dry eyes.

TheraLife® Eye Enhanced works from the inside out so that the tear secretion is sustainable throughout the day.

TheraLife® Eye Enhanced works without washing away the valuable mucin, lipids, and protein components that lubricate the eye – unlike eye drops applied to the eye’s surface, which can actually strip the eyes of its healthy, natural substances.

HORMONAL WELLNESS SUPPORT

TheraLife® Menopausal Support

This formula is designed for natural hormone balance. It contains black cohosh plus soy isoflavones and essential nutrients like calcium, folic acid, and B-vitamins to help balance hormonal levels and relieve symptoms of chronic dry eyes, hot flashes, night sweats, and more.

Women who are particularly concerned about synthetic hormones causing breast and ovarian cancer have used our all-natural formula as a safe and pure alternative.

ANTI-INFLAMMATORY SUPPORT

Omega 3 Fish Oil

We highly recommend molecularly distilled TheraLife® Omega 3 Fish Oil to be used in addition to TheraLife® Eye Enhanced formula, because of its strong anti-inflammatory and anti-oxidant properties.

COMPLETE DRY-EYE ROUTINE

All Natural Treatment For Dry Eyes- TheraLife

TheraLIfe Eye, warm compress – Chalazion Symptoms/ Blepharitis treatment winning combination that works.

Add To Cart

References

View scientific references

1 McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology. 1998;105:1114–9. – PubMed

1. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318–26. – PubMed
2. Ablamowicz AF, Nichols JJ, Nichols KK. Association between serum levels of testosterone and estradiol with meibomian gland assessments in postmenopausal women. Invest Ophthalmol Vis Sci. 2016;57:295–300. – PMC – PubMed

View scientific references — collection 2

1.: McNeil MA, Merriam SB. Menopause. Ann Intern Med. 2021 Jul;174(7):ITC97-ITC112. [PubMed]
2.: US Preventive Services Task Force. Mangione CM, Barry MJ, Nicholson WK, Cabana M, Caughey AB, Chelmow D, Coker TR, Davis EM, Donahue KE, Jaén CR, Kubik M, Li L, Ogedegbe G, Pbert L, Ruiz JM, Stevermer J, Wong JB. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement. JAMA. 2022 Nov 01;328(17):1740-1746. [PubMed]
3.: Hall JE. Endocrinology of the Menopause. Endocrinol Metab Clin North Am. 2015 Sep;44(3):485-96. [PMC free article] [PubMed]
4.: Tanbo TG, Fedorcsak PZ. Can time to menopause be predicted? Acta Obstet Gynecol Scand. 2021 Nov;100(11):1961-1968. [PubMed]
5.: Talaulikar V. Menopause transition: Physiology and symptoms. Best Pract Res Clin Obstet Gynaecol. 2022 May;81:3-7. [PubMed]
6.: Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ., STRAW+10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric. 2012 Apr;15(2):105-14. [PMC free article] [PubMed]
7.: Crandall CJ, Mehta JM, Manson JE. Management of Menopausal Symptoms: A Review. JAMA. 2023 Feb 07;329(5):405-420. [PubMed]
8.: Burkard T, Moser M, Rauch M, Jick SS, Meier CR. Utilization pattern of hormone therapy in UK general practice between 1996 and 2015: a descriptive study. Menopause. 2019 Jul;26(7):741-749. [PubMed]
9.: Williams M, Richard-Davis G, Weickert V, Christensen L, Ward E, Schrager S. A review of African American women’s experiences in menopause. Menopause. 2022 Nov 01;29(11):1331-1337. [PubMed]
10.: Polo-Kantola P, Rantala MJ. Menopause, a curse or an opportunity? An evolutionary biological view. Acta Obstet Gynecol Scand. 2019 Jun;98(6):687-688. [PubMed]
11.: Wang X, Wang L, Xiang W. Mechanisms of ovarian aging in women: a review. J Ovarian Res. 2023 Apr 06;16(1):67. [PMC free article] [PubMed]
12.: Shifren JL. Genitourinary Syndrome of Menopause. Clin Obstet Gynecol. 2018 Sep;61(3):508-516. [PubMed]
13.: Khandelwal S, Meeta M, Tanvir T. Menopause hormone therapy, migraines, and thromboembolism. Best Pract Res Clin Obstet Gynaecol. 2022 May;81:31-44. [PubMed]
14.: Soares CN. Depression and Menopause: An Update on Current Knowledge and Clinical Management for this Critical Window. Med Clin North Am. 2019 Jul;103(4):651-667. [PubMed]
15.: de Kruif M, Spijker AT, Molendijk ML. Depression during the perimenopause: A meta-analysis. J Affect Disord. 2016 Dec;206:174-180. [PubMed]
16.: El Khoudary SR, Greendale G, Crawford SL, Avis NE, Brooks MM, Thurston RC, Karvonen-Gutierrez C, Waetjen LE, Matthews K. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN). Menopause. 2019 Oct;26(10):1213-1227. [PMC free article] [PubMed]
17.: Lee JH, Lee JE, Harsh V, Clayton AH. Pharmacotherapy for Sexual Dysfunction in Women. Curr Psychiatry Rep. 2022 Feb;24(2):99-109. [PubMed]
18.: Moolhuijsen LME, Visser JA. Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function. J Clin Endocrinol Metab. 2020 Nov 01;105(11):3361-73. [PMC free article] [PubMed]
19.: Voedisch AJ, Ariel D. Perimenopausal contraception. Curr Opin Obstet Gynecol. 2020 Dec;32(6):399-407. [PubMed]
20.: Davis SR, Baber RJ. Treating menopause – MHT and beyond. Nat Rev Endocrinol. 2022 Aug;18(8):490-502. [PubMed]
21.: Liu JH. Selective estrogen receptor modulators (SERMS): keys to understanding their function. Menopause. 2020 Oct;27(10):1171-1176. [PubMed]
22.: “The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023 Jun 01;30(6):573-590. [PubMed]
23.: Menown SJ, Tello JA. Neurokinin 3 Receptor Antagonists Compared With Serotonin Norepinephrine Reuptake Inhibitors for Non-Hormonal Treatment of Menopausal Hot Flushes: A Systematic Qualitative Review. Adv Ther. 2021 Oct;38(10):5025-5045. [PMC free article] [PubMed]
24.: Reid IR, Billington EO. Drug therapy for osteoporosis in older adults. Lancet. 2022 Mar 12;399(10329):1080-1092. [PubMed]
25.: Stuenkel CA, Gompel A, Davis SR, Pinkerton JV, Lumsden MA, Santen RJ. Approach to the Patient With New-Onset Secondary Amenorrhea: Is This Primary Ovarian Insufficiency? J Clin Endocrinol Metab. 2022 Feb 17;107(3):825-835. [PubMed]
26.: Singh N, Sethi A. Endometritis – Diagnosis,Treatment and its impact on fertility – A Scoping Review. JBRA Assist Reprod. 2022 Aug 04;26(3):538-546. [PMC free article] [PubMed]
27.: Ambikairajah A, Walsh E, Cherbuin N. A review of menopause nomenclature. Reprod Health. 2022 Jan 31;19(1):29. [PMC free article] [PubMed]
28.: Wu D, Cline-Smith A, Shashkova E, Perla A, Katyal A, Aurora R. T-Cell Mediated Inflammation in Postmenopausal Osteoporosis. Front Immunol. 2021;12:687551. [PMC free article] [PubMed]
29.: Stuenkel CA, Manson JE. Compounded Bioidentical Hormone Therapy: The National Academies Weigh In. JAMA Intern Med. 2021 Mar 01;181(3):370-371. [PubMed]

CUSTOMER STORY

Testimonial

Noticed A Huge Difference

I was suffering from hormonally-related dry eye symptoms, exacerbated by a powerful air-conditioning/heating system in my office. I tried every kind of drop on the market to no avail and was considering getting a prescription. Then I heard about TheraLife and decided to give it a try. I noticed a huge difference within a couple of days, and 6 months later I had virtually no symptoms at all. I’ve been taking TheraLife regularly for a few years now and my eyes feel great! I truly can’t recommend this product highly enough.
*Note: Results may vary.*
Julie S.

THERALIFE SUPPORT

Build a supportive eye-wellness routine through menopause

Explore targeted products or contact the TheraLife team for practical guidance.

Sign In

Account

Secure

My Cart